ReACp53

ReACp53 is a rationally designed, cell-penetrating 17–amino acid peptide that inhibits amyloid-like aggregation of mutant p53 and thereby restores its tumor suppressor functions in cancer cells. By binding to aggregation-prone motifs within p53, ReACp53 prevents or reverses cytosolic amyloid assembly, relocalizes mutant p53 to the nucleus in an active conformation, reactivates transcription of p53 target genes such as p21, and promotes mitochondrial apoptosis through enhanced interaction with proapoptotic Bcl-2 family proteins including Bax.[1][7][15] Preclinical studies in high-grade serous ovarian carcinoma and castration-resistant prostate cancer models show that ReACp53 selectively impairs viability and proliferation of mutant p53–bearing cells, induces cell-cycle arrest and cell death, and suppresses xenograft tumor growth following intraperitoneal dosing, supporting its development as a targeted therapy for p53-mutant solid tumors.[1][6][7][10][15]

Other names

ReACp53 peptideReACp-53 peptideReACp 53 peptide